BLIS TechnologiesNZSE:BLT EBITDA Margin % is 9.34% as of Mar. 2026, which is 1% below its 10-year median of 9.45. The stock has 4 warning signs investors should review. Among 944 Biotechnology companies, BLIS Technologies ranks better than 74.26% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. BLIS Technologies's EBITDA for the
six
months ended in Mar. 2026 was NZ$0.58 Mil. BLIS Technologies's Revenue for the
six
months ended in Mar. 2026 was NZ$6.23 Mil. Therefore, BLIS Technologies's EBITDA margin for the quarter that ended in Mar. 2026 was 9.34%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
BLIS Technologies EBITDA Margin % Related Terms
BLIS Technologies EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for BLIS Technologies's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NZSE:BLT vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, BLIS Technologies's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BLIS Technologies EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BLIS Technologies's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where BLIS Technologies's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BLIS Technologies (NZSE:BLT) has a EBITDA Margin % of 9.34% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on BLIS Technologies and its competitors. This is near median its historical median of 9.45. According to the industry distribution chart, BLIS Technologies ranks #243 out of 944 companies in the Biotechnology industry, placing it in the top 25.7%.
Is BLIS Technologies' EBITDA Margin % too high?
BLIS Technologies' current EBITDA Margin % of 9.34% is near median its 10-year median of 9.45. Based on the distribution chart, BLIS Technologies ranks #243 out of 944 companies in the Biotechnology industry, which is above the industry midpoint.
How does BLIS Technologies' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BLIS Technologies ranks #243 out of 944 companies for EBITDA Margin %. This puts BLIS Technologies in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on BLIS Technologies and its competitors. BLIS Technologies's current EBITDA Margin % is 9.34%, which is near median its own 10-year median of 9.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BLIS Technologies stock overvalued right now?
Based on GuruFocus' analysis, BLIS Technologies (NZSE:BLT) is currently considered Modestly Undervalued. The stock's GF Value™ is NZ$0.02, compared to a current price of NZ$0.02 — trading 20% below its estimated fair value. The current EBITDA Margin % is 9.34%, which is near median its 10-year median of 9.45. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For BLIS Technologies (NZSE:BLT), the current EBITDA Margin % is 9.34% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BLIS Technologies Ltd is engaged in developing oral probiotics. The company markets strains of probiotic bacteria BLIS K12, BLIS Q24, and BLIS M18, which occur naturally in the oral cavity. Its product portfolio consists of probiotic serum, Teeth and gums lozenge, fresh breath lozenge, and immune lozenge. Geographically, the company derives a majority of its revenue from North America. The company also generates a small portion of revenue from Non-core business, which includes grants and interest revenue.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NZSE:BLT has been successfully added to your 